Svizzera - Taljan - Swissmedic (Swiss Agency for Therapeutic Products)

streuli pharma ag - glibenclamidum - compresse - glibenclamidum 5 mg, lactosum monohydricum 135 mg, maydis amylum, carmellosum natricum corresp. natrium max. 0.042 mg, talcum, magnesii stearas, pro compresso. - farmaco antidiabetico orale - synthetika

Svizzera - Taljan - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - insulinum glarginum - soluzione iniettabile - insulinum glarginum 3.6378 mg corresp. insulinum glarginum 100 u., zinci chloridum, glycerolum (85 per centum), acidum hydrochloridum concentratum, natrii hydroxidum 0.1 mg, metacresolum, aqua ad iniectabile ad solutionem pro 1 ml. - il diabete mellito - biotechnologika

Svizzera - Taljan - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - insulinum glarginum - soluzione iniettabile in penna pre-riempita - insulinum glarginum 10.91 mg corresp. insulinum glarginum 300 u., zinci chloridum, glycerolum (85 per centum), acidum hydrochloridum concentratum, natrii hydroxidum q.s. ad ph, metacresolum, aqua ad iniectabile ad solutionem pro 1 ml. - il diabete mellito - biotechnologika

Svizzera - Taljan - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - nusinersenum - soluzione per iniezione intrathekalen - solvens: nusinersenum 12 mg ut nusinersenum natricum, natrii dihydrogenophosphas dihydricus, dinatrii phosphas, natrii chloridum, kalii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, natrii hydroxidum, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 5 ml. - trattamento della 5q associati ad atrofia muscolare spinale (sma) - synthetika

Italja - Taljan - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - gliclazide - gliclazide

Unjoni Ewropea - Taljan - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - infezioni da hiv - antivirali per uso sistemico - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Unjoni Ewropea - Taljan - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Unjoni Ewropea - Taljan - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - atrofia muscolare, spinale - altri farmaci per i disturbi del sistema muscolo-scheletrico - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Unjoni Ewropea - Taljan - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomioma - ormoni ipofisari e ipotalamici e analoghi - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Unjoni Ewropea - Taljan - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosoppressori - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.